Onconova Therapeutics Inc (ONTX)

1.74
0.04 2.20
NASDAQ : Health Care
Prev Close 1.78
Open 1.80
Day Low/High 1.72 / 1.82
52 Wk Low/High 3.30 / 40.00
Volume 13.83K
Avg Volume 37.60K
Exchange NASDAQ
Shares Outstanding 9.85M
Market Cap 16.25M
EPS -4.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Onconova Therapeutics, Inc. To Provide Corporate Update And Second Quarter 2017 Financial Results

Onconova Therapeutics, Inc. To Provide Corporate Update And Second Quarter 2017 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, August 15, 2017

Onconova Therapeutics, Inc. To Provide Corporate Update And First Quarter 2017 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Monday, May 15, 2017

Onconova Therapeutics Announces Pricing Of Public Offering Of Common Stock

Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes

Onconova Therapeutics Announces Proposed Public Offering Of Common Stock

Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes

Onconova Therapeutics, Inc. To Provide Corporate Update And Full Year 2016 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Monday, March 27, 2017

5 Stocks Under $10 That Could Rocket Higher Soon

5 Stocks Under $10 That Could Rocket Higher Soon

Keep an eye on these cheap stocks.

These 5 Stocks Under $10 Could Get Hot Soon

These 5 Stocks Under $10 Could Get Hot Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Onconova And Cellworks Announce Presentation Of Rigosertib Predictive Signature For Clinical Response In Myelodysplastic Syndromes (MDS) At 2016 ASH Annual Meeting

Onconova And Cellworks Announce Presentation Of Rigosertib Predictive Signature For Clinical Response In Myelodysplastic Syndromes (MDS) At 2016 ASH Annual Meeting

Computational Subgroup Analysis of Phase 3 ONTIME Trial Provides Insights into Clinical Response to Rigosertib in Higher-risk MDS

TheStreet Quant Rating: E+ (Sell)